Company profile

Ticker
BMY
Exchange
Employees
Incorporated in
Location
Fiscal year end
SEC CIK
IRS number
220790350

Calendar

7 May 20
2 Jul 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue 10.78B 7.95B 6.01B 6.27B
Net income -766M -1.06B 1.37B 1.44B
Net profit margin -7.11% -13.34% 22.74% 22.94%
Net change in cash 3.47B -18.14B 2.09B 21.07B
Cash on hand 15.82B 12.35B 30.49B 28.4B
Cost of revenue 3.66B 2.43B 1.81B 1.99B
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 26.15B 22.56B 20.78B 19.43B
Net income 3.46B 4.95B 975M 4.51B
Net profit margin 13.23% 21.93% 4.69% 23.20%
Net change in cash 5.44B 1.49B 1.18B 1.85B
Cash on hand 12.35B 6.91B 5.42B 4.24B
Cost of revenue 8.08B 6.47B 6.01B 4.97B

Financial data from company earnings reports

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
1 Jul 20 Santiago Karen Murphy Common Stock, $0.10 par value Payment of exercise Dispose F 59.43 367 21.81K 7,748
1 Jul 20 Santiago Karen Murphy Common Stock, $0.10 par value Option exercise Aquire M 0 1,069 0 8,115
1 Jul 20 Santiago Karen Murphy RSU Common Stock, $0.10 par value Option exercise Dispose M 0 1,069 0 3,208
1 Jul 20 Hirawat Samit Common Stock, $0.10 par value Payment of exercise Dispose F 59.43 4,463 265.24K 4,893
1 Jul 20 Hirawat Samit Common Stock, $0.10 par value Option exercise Aquire M 0 9,356 0 9,356
1 Jul 20 Hirawat Samit RSU Common Stock, $0.10 par value Option exercise Dispose M 0 9,356 0 28,069
30 Jun 20 Emmens Matthew Deferred Share Units Common Stock, $0.10 par value Grant Aquire A 58.8 616.497 36.25K 21,667.561
30 Jun 20 Michael W Bonney Deferred Share Units Common Stock, $0.10 par value Grant Aquire A 58.8 392.432 23.08K 4,639.199
30 Jun 20 Bertolini Robert J Deferred Share Units Common Stock, $0.10 par value Grant Aquire A 58.8 595.238 35K 21,384.859
97.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2172 2168 +0.2%
Opened positions 209 468 -55.3%
Closed positions 205 94 +118.1%
Increased positions 1004 1188 -15.5%
Reduced positions 763 379 +101.3%
13F shares
Current Prev Q Change
Total value 912.17B 1.12T -18.6%
Total shares 2.21B 1.77B +24.8%
Total puts 30.1M 64.67M -53.5%
Total calls 30.05M 24.9M +20.7%
Total put/call ratio 1.0 2.6 -61.4%
Largest owners
Shares Value Change
Vanguard 198.9M $11.09B +2.1%
BLK BlackRock 172.62M $9.51B +0.7%
STT State Street 100.9M $5.62B +1.1%
FMR 77.12M $3.88B +6.5%
Wellington Management 75.51M $4.21B -9.5%
Renaissance Technologies 75.42M $3.71B +25.3%
JPM JPMorgan Chase & Co. 73.67M $3.42B +43.1%
Pentwater Capital Management 53.01M $201.44M NEW
Laurion Capital Management 48.54M $348.2M NEW
Geode Capital Management 40.33M $2.24B +4.9%
Largest transactions
Shares Bought/sold Change
Pentwater Capital Management 53.01M +53.01M NEW
Laurion Capital Management 48.54M +48.54M NEW
Farallon Capital Management 35.2M +35.2M NEW
Norges Bank 0 -27.06M EXIT
Abrams Capital Management 23.2M +23.2M NEW
JPM JPMorgan Chase & Co. 73.67M +22.19M +43.1%
Citadel Advisors 23.86M +21.08M +758.2%
Viking Global Investors 19.64M +19.64M NEW
Renaissance Technologies 75.42M +15.21M +25.3%
CS Credit Suisse 25.35M +14.58M +135.3%

Financial report summary

?
Risks
  • The COVID-19 pandemic is affecting our business and could have a material adverse effect on us.
  • It is possible that the COVID-19 pandemic could delay the timing of the FDA’s approval decisions for liso-cel and ide-cel, which could have a material adverse effect on our contingent value rights (CVRs).
Management Discussion
  • U.S. revenues for the three months ended March 31, 2020 were impacted by $2.8 billion from Revlimid and other Celgene products, which contributed 81% of the growth and higher demand for Eliquis. Changes in buying patterns resulting from COVID-19 pandemic contributed approximately $300 million of revenues. Average net selling prices, including Celgene products, increased 3% for the three months ended March 31, 2020.
  • Europe revenues for the three months ended March 31, 2020 were impacted by $965 million from Celgene products, which contributed 65% of the growth, the change in buying patterns resulting from the COVID-19 pandemic and higher demand for Eliquis and Opdivo, partially offset by foreign exchange and lower demand for established brands. Average net selling prices, including Celgene products, were lower for the three months ended March 31, 2020.
  • Rest of the World revenues for the three months ended March 31, 2020 were impacted by $477 million from Celgene products, which contributed 55% of the growth, the change in buying patterns resulting from the COVID-19 pandemic and higher demand for Opdivo and Eliquis, partially offset by foreign exchange and lower demand for established brands. Average net selling prices, including Celgene products, were lower for the three months ended March 31, 2020.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: Abraxane, Acceleron, acid, acknowledged, adjudication, administered, albumin, ALK, allegedly, AML, analog, anemia, answer, anticompetitive, antidilutive, appointed, appointment, arrangement, ASC, assistance, atrioventricular, Aurobindo, Aurolife, avoid, avoidance, awarding, azacitidine, back, banking, behavior, beta, bioequivalence, Biohaven, BLA, Boehringer, breadth, breast, Breckenridge, broad, broader, buying, Cabometyx, Canadian, capped, CAR, carboplatin, cell, CEO, certified, Chair, CheckMate, CHMP, choose, chose, Cipla, cisplatin, collar, collect, collected, Columbia, Commonwealth, computation, confirmatory, conspiracy, contrast, Corrupt, counsel, count, County, cyber, daily, decided, declaratory, deficient, Deloitte, deoxyribonucleic, departure, deplete, deploy, deteriorating, disaster, discretionary, disruption, disruptive, distancing, distinct, dosage, downturn, Dr, DRL, dual, dynamic, economy, EGFR, EMA, emanating, emerged, encourage, engineering, England, enrichment, enrolled, enrolling, enrollment, environment, equivalent, erythroid, escrow, Eugia, exacerbate, exhausted, exit, expenditure, exposure, Fast, fedratinib, field, firm, follicular, Francisco, FZE, gastric, gave, gene, genetic, Genitourinary, genomic, Gilead, hematopoietic, Hetero, histology, home, Humana, hypermethylation, hypomethylating, idecabtagene, imaging, immune, immunomodulatory, Imnovid, incomplete, India, induction, ineligible, Ingelheim, Inrebic, insignificant, intervention, issuer, Janssen, Journal, Juno, Kettering, key, Kite, large, largely, larger, lengthen, leverage, lisocabtagene, LLC, LLP, lymphoma, maker, malware, maraleucel, marginal, maximize, MDS, meaningful, medicine, mesylate, MHLW, Minister, Minnesota, mismatch, misrepresentation, mitigate, mitigation, modulator, MPM, mutational, mutationally, myelodysplastic, nab, Natco, nationwide, NDA, negligent, neoplasm, neutropenia, NMPA, nucleoside, Nurtec, ODT, Ontario, opportunity, opposed, opted, organizational, outlook, outsourcing, ovarian, overarching, ozanimod, paclitaxel, pandemic, paragraph, PDUFA, peak, pemetrexed, personnel, Pharma, pharmacy, phishing, physical, Pike, pivotal, placebo, plaintiff, platform, pleading, polymorphic, Pomalyst, postponed, prejudgment, preliminary, prescribing, principle, procuring, prolonged, proper, proposition, protocol, Provision, public, published, punitive, pyrimidine, quantify, QUAZAR, Quebec, quickly, Racketeer, rapidly, ratified, RBC, reach, reached, ready, Reblozyl, receptor, reclassed, recovery, red, Reddy, refile, refinance, refused, refusing, registered, rejected, rely, remission, remote, repair, replacement, resale, resource, resume, retiree, revalued, reverted, rimegepant, ring, ringed, RMS, running, safe, scheme, Schwab, science, screening, secondary, serve, sharp, shelter, shift, short, shorten, shown, similarly, situation, SKI, Sloan, social, solvency, sponsoring, stem, stemming, stimulating, strain, strike, sudden, Sun, sunitinib, Symposium, syndrome, tailored, technology, temporary, Territory, Teva, thalassemia, thalidomide, Thalomid, threatened, thrombocythemia, thrombocytopenia, titled, top, Touche, Track, transient, transplant, transplantation, travel, treble, Trust, type, UHS, unemployment, unenforceable, unfair, unjust, unjustified, unlawful, unprecedented, unpredictable, unsatisfactory, unvested, unwind, unwinding, upper, upward, USA, valuation, variation, vera, verification, vicleucel, Vidaza, ViiV, Virtually, vision, Visit, volatility, voucher, wave, weighted, welfare, wild, willfully, workplace, worse, Yescarta, Zeposia, zone
Removed: achievement, acquire, ACS, Additionally, adjuvant, age, agreed, ahead, alive, allocated, amending, announcement, annuity, antiplatelet, applied, apply, aspirin, assessing, asymptomatic, Athene, Autoinjector, automatic, bleeding, borrowed, borrowing, BRAF, breached, build, Burgundy, Chancery, charge, classified, close, closing, cold, commenced, commercialized, committed, comprised, concurrently, conditioned, consist, consummation, continuously, converting, credited, CreditWatch, criteria, CRNM, Dafalgan, deal, declaring, delivering, depart, developing, direction, disciplined, discontinue, discovering, disputed, diversified, Division, dMMR, documentary, drawn, EC, Efferalgan, ehf, eliminate, eliminating, enable, enjoin, entity, EPO, Erbitux, ERISA, essential, estate, evidence, exemption, expedient, expired, exploratory, extend, extension, Fervex, fiduciary, finalization, financed, flat, flu, fluctuate, focused, formed, fourteenth, France, funding, governing, growing, guarantee, hearing, hormone, HSR, immunoscience, implicit, importance, Importantly, incremental, indemnity, informing, inhibition, initially, instrument, intermediate, IO, Ireland, JNDA, label, lease, leased, leasehold, loan, match, mCRPC, Medarex, median, megabase, merged, merger, meslylate, minimally, Mutant, Notably, notification, older, ordering, orphan, package, participant, payable, PCI, permitted, pooled, positioned, Post, powder, practical, practice, prepaid, principally, produce, proportion, prospectively, PTC, ranging, real, receive, recognize, redemption, reliable, removed, renew, renewal, representing, restrictive, retained, revoked, roughly, RRMM, satisfaction, SCCHN, senior, showed, showing, sJNDA, solicited, solution, specialty, Step, storage, strength, styled, symptomatic, tablet, TMB, tradeable, tranche, transformational, undergoing, uniQure, unnamed, upheld, Vehicle, verify, vitamin, VKA, waiting, week